Bortezomib in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with
metastatic kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)